Two validated liquid chromatography–mass spectrometry methods with different pretreatments for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum compared with an electrochemiluminescence method

Gao, Yuxiong; Zhang, Dan; Yang, Changyong; Duan, Xiaotao; Li, Xiuli; Zhong, Dafang

doi:10.1016/j.jpba.2019.112792

Cited by 7 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two validated liquid chromatography-mass spectrometry methods had been developed with different pretreatments for the quantification of an anti-CD47 mAb in rat and cynomolgus monkey serum compared with an electrochemiluminescence method. The established LC–MS methods exhibited superior accuracy, efficiency and cost-effectiveness for the PK assessment of SHR-1603 in the preclinical study [ 77 ]. At present, there is one clinical trial in the NCT (NCT03722186) and CDT (CTR20181964) systems in the suspended status.…”

Section: The Clinical Development Of Anti-cd47 Mabs In Chinamentioning

confidence: 99%

Targeting CD47 for cancer immunotherapy

et al. 2021

View full text Add to dashboard Cite

Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 2021, there are a total 23 related therapeutic agents with 46 clinical trials in the NCT registry platform. Among these trials, 29 are in ST, 14 in hematological malignancies and 3 in both solid tumor and hematological malignancy. The ST include gastric cancer, head and neck squamous cell carcinoma and leiomyosarcoma, while the hematological malignancies include non-Hodgkin's lymphoma, acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and chronic myeloid leukemia. Majority of the CD47-related clinical trials are at the early phases, such as 31 at phase I, 14 at phase II and 1 at phase III in the USA and 9, 6, 1, in China, respectively. The targets and spectrums of mechanism of action include 26 with mono-specific and 20 with bi-specific targets in the USA and 13 with mono-specific and 3 with bi-specific targets in China. The new generation CD47 antibodies have demonstrated promising results, and it is highly hopeful that some candidate agents will emerge and make into clinical application to meet the urgent needs of patients.

show abstract

Section: The Clinical Development Of Anti-cd47 Mabs In Chinamentioning

confidence: 99%

Targeting CD47 for cancer immunotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition to avelumab, other anti-ICPML mAbs with preserved effector functions are at various stages of preclinical or clinical development. These include antibodies against CD40 [106], CD47 [107,108], PD-L1 [109], CD70 [110] and B7-H4 [111]. Also in these cases, for all the more reason, it is presently impossible to estimate the contribution of the effector functions to the (potential) therapeutic efficacy of these antibodies.…”

Section: Does Target Cell Depletion Contribute To the Therapeutic Activity Of Some Of The Approved Icis?mentioning

confidence: 99%

Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer

Marcucci

Rumio

2021

Cells

View full text Add to dashboard Cite

Antibodies against inhibitory immune checkpoint molecules (ICPMs), referred to as immune checkpoint inhibitors (ICIs), have gained a prominent place in cancer therapy. Several ICIs in clinical use have been engineered to be devoid of effector functions because of the fear that ICIs with preserved effector functions could deplete immune cells, thereby curtailing antitumor immune responses. ICPM ligands (ICPMLs), however, are often overexpressed on a sizeable fraction of tumor cells of many tumor types and these tumor cells display an aggressive phenotype with changes typical of tumor cells undergoing an epithelial-mesenchymal transition. Moreover, immune cells expressing ICPMLs are often endowed with immunosuppressive or immune-deviated functionalities. Taken together, these observations suggest that compounds with the potential of depleting cells expressing ICPMLs may become useful tools for tumor therapy. In this article, we summarize the current state of the art of these compounds, including avelumab, which is the only ICI targeting an ICPML with preserved effector functions that has gained approval so far. We also discuss approaches allowing to obtain compounds with enhanced tumor cell-depleting potential compared to native antibodies. Eventually, we propose treatment protocols that may be applied in order to optimize the therapeutic efficacy of compounds that deplete cells expressing ICPMLs.

show abstract

“…Finally, this SOD method was applied in a full‐profile pharmacokinetic study, and data on highly accurate and precise SOD method for protein quantitation in plasma samples were presented in their article. Besides, Gao and co‐workers () achieved sufficient digestion efficiency by improving the incubation temperature to 60°C and optimizing the reaction time to 1.5 h, resulting in an LLOQ value of 250 ng/mL for an anti‐CD47 monoclonal antibody (SHR‐1603).…”

Section: Sample Clean‐up and Recoverymentioning

confidence: 99%

Technologies to improve the sensitivity of existing chromatographic methods used for bioanalytical studies

Chen

Gao

Zhong

2020

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

Chromatographic method has long been recognized as the most widely used separation method in bioanalytical research. However, the relatively low sensitivity of existing chromatographic methods remains a significant challenge, as the requirements for experimental procedures become more demanding. This review discusses the main causes for the low sensitivity of chromatographic methods and aims to introduce different technologies for enhancing their sensitivity in the following aspects: (i) different pretreatment methods for improving clean‐up efficiency and recovery; (ii) derivatization step for altering the chromatographic behavior of analytes and enhancing MS ionization efficiency; (iii) optimal LC–MS conditions and appropriate separation mechanism; and (iv) applications of other chromatographic methods, including miniaturized LC, 2D‐LC, 2D‐GC, and supercritical fluid chromatography. Altogether, this review is devoted to summarizing the recent technologies reported in the literature and providing new strategies for the detection of bioanalytes.

show abstract

Two validated liquid chromatography–mass spectrometry methods with different pretreatments for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum compared with an electrochemiluminescence method

Cited by 7 publications

References 20 publications

Targeting CD47 for cancer immunotherapy

Targeting CD47 for cancer immunotherapy

Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer

Technologies to improve the sensitivity of existing chromatographic methods used for bioanalytical studies

Contact Info

Product

Resources

About